Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Elacestrant

The articles shown below are all about the Elacestrant, through these related articles, you can get relevant information, notes in use, or latest trends about the Elacestrant. We hope these news will give you the help you need. And if these Elacestrant articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    2024-12-23

    This week, there are 4 drugs in the patent and exclusivity list. They are: - STEMLINE THERAPEUTICS INC's ORSERDU, containing active ingredient ELACESTRANT DIHYDROCHLORIDE - ABBVIE INC's UBRELVY, containing active ingredient UBROGEPANT - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's AUSTEDO, containing active ingredient DEUTETRABENAZINE - OTSUKA PHARMACEUTICAL CO LTD's REXULTI, containing active ingredient BREXPIPRAZOLE Read More
  • Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    2024-10-10

    IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More
  • Drug Briefing: Elacestrant

    Drug Briefing: Elacestrant

    2024-10-08

    Query Drug：ElacestrantQuery Time：2024-10-08 16:20:43*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More